Clinical Trials

Prostatic Neoplasms

NCT01171898 2026-05-11

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Phase 1/2 Completed

127 enrolled 16 charts

Prostatic Neoplasms

NCT04987203 2026-05-08

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

Phase 3 Completed

343 enrolled

Carcinoma, Renal Cell, Disease Progression

NCT05114746 2026-05-08

Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan

Phase 2 Completed

94 enrolled

Prostatic Neoplasms

NCT05005728 2026-05-05

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

72 enrolled

Prostatic Neoplasms

NCT07561502 2026-05-01

PERI III

Phase NA Completed

32 enrolled

Prostatic Neoplasms

NCT05177042 2026-04-28

Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer

45 enrolled 23 charts

Prostatic Neoplasms

NCT06104449 2026-04-27

MK-5684-005

7 enrolled

Prostatic Neoplasms

NCT04943380 2026-04-24

DRIVE

682 enrolled

Carcinoma, Transitional Cell, Hematuria

NCT04523207 2026-04-21

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

Phase 2 Completed

108 enrolled 13 charts

Prostatic Neoplasms

NCT02695121 2026-04-17

Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment

2,133,575 enrolled

BreastGenitourinary

Urinary Bladder Neoplasms, Breast Neoplasms

NCT05022849 2026-04-17

A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

15 enrolled

Prostatic Neoplasms

NCT05461430 2026-04-13

TraveraRTGx

BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

72 enrolled

Anus Neoplasms, Appendiceal Neoplasms, Ascites, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Laryngeal Neoplasms, Lung Neoplasms, Melanoma, Mesothelioma, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasms, Unknown Primary, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Penile Neoplasms, Stomach Neoplasms, Thymoma, Vulvar Neoplasms, Pleural Effusion, Malignant, Carcinoma, Neuroendocrine, Cholangiocarcinoma, Carcinoma, Small Cell, Carcinoma, Pancreatic Ductal, Gastrointestinal Stromal Tumors

NCT06973161 2026-04-08

ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

GastrointestinalGenitourinaryGynecologicThoracic

140 enrolled

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04582656 2026-04-06

VIOLETTE

Phase NA Completed

76 enrolled

Neoplasms, Prostatic Neoplasms

NCT04822350 2026-04-02

AVENANCE

596 enrolled 43 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03798626 2026-04-01

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

GastrointestinalGenitourinary

167 enrolled

Carcinoma, Renal Cell, Colorectal Neoplasms

NCT06136598 2026-03-19

MK-5684-001

14 enrolled

Prostatic Neoplasms

NCT07477756 2026-03-19

A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients

1,247 enrolled

Prostatic Neoplasms

NCT06108479 2026-03-18

Study of DF6215 in Patients With Advanced Solid Tumors

DermatologicGenitourinaryGynecologicHead & NeckThoracic

35 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms

NCT06894771 2026-03-16

MK-4700-001